Background: We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC). Results: The study cohort consisted of 32 patients with a median age of 53 years. Overall response rate was 6.3%
introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with increasing incidence and the third most common cause of cancer-related death. HCC is responsible for 600 000 deaths/year, which is >95% of those of new HCC cases diagnosed each year [1] . The high mortality rate for HCC is due to limited treatment options. Only 10%-30% of cases are suitable for the current curative treatments which include surgical resection, liver transplantation and local ablation with alcohol [percutaneous ethanol injection (PEI)] and radiofrequency ablation (RFA) [2] . In addition, 90% of HCC patients develop cirrhosis. Therefore, treatment of HCC must address liver function as well as growth and metastasis.
Transarterial chemoembolization (TACE) is the recommended first-line noncurative therapy for inoperable patients with large multifocal HCC [3] because it has been shown to have survival benefits in recent randomized controlled trials [4, 5] . However, TACE is indicated for patients who have good liver function, good performance status (PS), no portal hypertension and no portal vein thrombosis (PVT) [3] . Therefore, systemic treatment is necessary for the majority of advanced-stage HCC patients and those with recurrence after curative treatment because they generally have multifocal and disseminated HCC.
Doxorubicin as a single agent showed a small but significant overall survival (OS) gain compared with supportive care but had fatal toxicity in 25% of patients [6] . Single or combined regimens of other drugs, including 5-fluorouracil (5-FU), capecitabine, cisplatin, oxaliplatin, gemcitabine, mitoxantrone, epirubicin, irinotecan and sorafenib, have shown 0%-27% of response rate, 2-6 months of time to progression (TTP) or progression-free survival and 3-12 months of OS time [7] [8] [9] [10] [11] [12] [13] [14] [15] . However, there is currently no standard systemic chemotherapy for patients with advanced HCC.
5-FU is a commonly used single agent with modest antitumor activity and safety in patients with HCC [16] and has been used in numerous combination chemotherapy protocols [9, 14, 17] . Cisplatin also has modest activity as single-agent chemotherapy [18] and cisplatin-based combination regimens have shown 16%-27% of response rate [7, 9, 14] . Several studies demonstrated that intra-arterial combination chemotherapy with 5-FU and cisplatin (FP) had activity for HCC [19, 20] . Specifically, one systemic FP regimen had 47% of response rate with 7 months of TTP [21] . In addition, treatment of inoperable HCC with the systemic FP chemotherapy in our institution resulted in a 14.1% response rate, a 43.9% disease control rate, 2.4 months of TTP and 9.8 months of OS. Capecitabine is a tumor-selective fluoropyrimidine with the convenience of oral administration, while 5-FU is administered by infusion [22] . Treatment with capecitabine showed 11% of overall response rate including one complete remission and 22% of disease control rate with tolerable toxicity in 37 HCC patients with underlying liver cirrhosis [23] .
Therefore, in this study, we tested a combination chemotherapy regimen of capecitabine and cisplatin (XP) in patients with metastatic HCC. Response evaluation for intrahepatic lesion in patients with advanced HCC is not easy because of a variability of tumor growth pattern and results of previous local treatments including TACE, PEI and RFA. Therefore, current study selected advanced HCC patients with one more extrahepatic metastatic measurable lesion.
patients and methods eligibility
This study was conducted at the Seoul National University Hospital and Seoul National University Bundang Hospital. From September 2003 to July 2007, we enrolled patients with metastatic HCC who had measurable lesions and good liver function (Child-Pugh class A or B). Eligibility criteria included the following: (i) a pathologically defined or >2-cm mass in a cirrhotic liver and typical features of HCC on one dynamic imaging study or an a-fetoprotein (AFP) level >200 ng/ml, (ii) a 1-to 2-cm mass in a cirrhotic liver and typical features of HCC on two dynamic imaging studies [computed tomography (CT) scan and magnetic resonance imaging with contrast], according to American Association for the Study of Liver Diseases guideline [3] , (iii) at least one measurable extrahepatic lesion, (iv) no previous systemic chemotherapy, (v) an Eastern Cooperative Oncology Group (ECOG) PS of zero to two, (vi) a Child-Pugh class of A-B, (vii) an age of 18-70 years and (viii) adequate bone marrow, renal and hepatic function (absolute neutrophil count ‡ 1.5 · 10 9 /l and platelet count ‡ 50 · 10 9 /l; serum creatinine £ 1.5 mg/dl; aspartate aminotransferase and alanine aminotransferase £2.5· upper limits of normal; total bilirubin £1.5· upper limits of normal). Study entry required a complete medical history, a physical examination, a complete blood cell (CBC) with a differential count, a biochemistry panel, a coagulation panel and AFP, a chest radiograph and an abdominal and/or chest CT scan. This review of study was approved by the Institutional Review Board of the Seoul National University Hospital, Seoul, Korea. ) on the first day of the 3-week cycle. Each cycle of chemotherapy was given every 3 weeks and treatment was terminated if disease progressed, unacceptable toxicity was observed or upon patient refusal.
evaluation of response and toxicity CBC, blood chemistry and serum AFP were obtained before the beginning of each cycle. The response to treatment was evaluated every two cycles by means of CT scan or earlier if there were clinical signs of progression.
The RECIST (response evaluation criteria in soild tumors) guidelines were used to estimate antitumor response. Toxic effects were evaluated according to the National Cancer Institute-Common Toxicity Criteria version 3.0.
statistics
The primary objective of this study was to assess the overall response rate. The secondary objectives were to evaluate the OS, the TTP and toxicity. TTP was defined as the time interval from the first cycle of chemotherapy to the date that disease progression was first observed. OS was defined as the time interval between the first cycle of chemotherapy and death due to any cause or the last clinical follow-up. TTP and OS were assessed by the Kaplan-Meier method and differences between the curves were analyzed using the log-rank test. A Cox regression hazard model was used for multivariate Cox proportional analysis. All P values were two sided, with P < 0.05 indicating statistical significance. SPSS for windows (SPSS, Chicago, IL) was used for statistical analysis. The dose intensity (DI) was calculated as the ratio of the total dose (expressed in milligrams) per square meter of the patient divided by the total treatment duration expressed in days. The relative DI was calculated as the ratio of the DI actually delivered to the DI planned in the protocol. Table 1 . The study included 28 (87.5%) males, and the median age was 53 years (range 34-68 years). Of note, 28 patients (87.5%) had ECOG PS scores of zero to one, and 30 patients (93.8%) had good liver function and were Child-Pugh class A. Ten patients (31.3%) had PVT. Twenty-seven patients (84.4%) had hepatitis B (n = 25, 78.1%) or C (n = 2, 6.3%). Metastatic sites included the lung (n = 21), lymph node (n = 10), adrenal gland (n = 5), bone (n =5), peritoneal seeding (n = 3) and brain (n = 2). Patients with bone metastasis or peritoneal seeding also had another measurable metastatic lesion. Twenty-five of thirty-two patients had intrahepatic viable tumors. The majority of patients (n = 29, 90.6%) had received prior treatment of HCC including TACE (n = 26), curative surgical resection (n = 6), RFA (n = 5), liver transplantation (n = 4), PEI (n = 3), etc. The median time of TACE of the 26 patients was 3 times (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The median value of AFP was 705 ng/ml (range 3-254 000 ng/ml) and 19 patients (59.4%) had >200 ng/ml of AFP.
drug delivery
Drug delivery and relative DI are shown in Table 2 . In total, 92 cycles were administered with a median of two cycles per patient (range 1-9). The mean delivered DIs were 82.0% for capecitabine and 82.9% for cisplatin. Nineteen patients (59.4%) were treated with a >75% relative DI of capecitabine and cisplatin. Reduced doses were administered in 28 of 92 cycles (30.4%) for capecitabine and 21 of 92 cycles (22.8%) for cisplatin. The chemotherapy schedule was delayed in 29 of 92 cycles (31.5%).
efficacy and survival
Thirty-two (100%) patients were evaluated for tumor response. Five patients who received one cycle of XP also were evaluated Annals of Oncology original article and showed the disease progression. The RECIST (response evaluation criteria in soild tumors) guidelines were used to estimate antitumor response. The overall response rate was 6.3% and the disease control rate was 34.4% with two patients exhibiting partial response (PR) and nine exhibiting stable disease (SD). The duration of response of two responders was 3.8 and 8.5 months, and the median duration of disease stability of nine SD patients was 4.9 months (range 2.9-14.8).
Of 19 patients with baseline high AFP (>200 ng/ml), two patients who showed SD and progressive disease (PD) of radiological response also showed an AFP reduction of >50%, and three patients who showed two SD and one PD of radiological response also showed an AFP reduction of 25%-50%. Pre-AFP values of the two patients with PRs were 3 and 4 ng/ml and the follow-up AFP values for both were <5 ng/ml.
The median follow-up duration was 8.0 months. The median TTP was 2.0 months [95% confidence interval (CI) 1.5-2.4; Figure 1 ], and the median OS time was 12.2 months (95% CI 6.5-17.8; Figure 2) . We analyzed the relative TTP and OS according to 11 factors including age (£53 versus >53 years), sex, PS (ECOG 0-1 versus 2), Child-Pugh score (A versus B), PVT, etiology [hepatitis B virus (HBV) versus non-HBV], pre-AFP value (£705 versus >705 ng/ml), intrahepatic tumor viability and previous liver transplantation. Lower pre-AFP values (2.6 versus 1.5 months, P = 0.01) were significant factors correlating with TTP by univariate analysis (Table 3) . For OS, a Child-Pugh score (A versus B, 13.2 versus 3.0 months, P = 0.02), pre-AFP (£705 versus >705 ng/ml, 17.4 versus 3.9 months, P = 0.001) and previous liver transplantation (yes versus no, 13.2 versus 1.9 months, P = 0.02) were significant correlative factors by univariate analysis (Table 3) . A multivariate Cox proportional analysis of the above three factors showed that a higher pre-AFP (>705 ng/ml) and previous transplantation (TPL) were statistically significant prognostic factors for poor OS [hazard ratio (HR) = 4.70, 95% CI 1.73-12.80, P = 0.002; HR = 5.06, 95% CI 1.52-16.90, P = 0.008; Table 4 ]. Hematological and non-hematological toxic effects are described in Table 5 . Grade 3/4 hematologic toxic effects (per cycle) were thrombocytopenia (7.6%), neutropenia (4.3%) and anemia (2.1%). There were no neutropenic fever or bleeding events. Grade 3/4 non-hematologic toxic effects (per patient) included elevated hepatic aminotransferase in four patients (12.9%), jaundice in one patient (3.2%), mucositis in one patient (3.2%) and nausea in one patient (3.2%). Treatment withdrawal related to toxicity was applied to one patient who had prolonged grade 3 nausea. At the time of withdrawal, the tumor response to chemotherapy was categorized as SD. There was no treatment-related mortality.
discussion Recent large trials showed that sorafenib, a multikinase inhibitor, significantly increased OS in patients with advanced HCC [15, 24] and can be considered as a standard for advanced HCC. However, a subgroup analysis showed a relatively low survival benefit for sorafenib over placebo in patients with extrahepatic spread (HR = 0.55, 95% CI 0.39-0.77; HR = 0.85, 95% CI 0.64-1.14) [15] . Further studies are warranted to firm the role of sorafenib for advanced HCC in various clinical settings. Additional studies of potential systemic chemotherapy regimens for the treatment of advanced HCC are also needed. The current study was initiated to determine whether a combination of capecitabine and cisplatin (XP), which have both been shown to be active and safe drugs as single or combination therapies in previous studies, could have synergic effects. Synergistic enhancement was observed with the combination of 5-FU and cisplatin in human hepatoma cell lines [25] . The results of the current study showed that this XP regimen has minimal antitumor activity and tolerable toxicity. Several factors should be considered when comparing the results of this study to previous studies. First, the heterogeneity of different study populations can affect results. Unlike other solid tumors, a varied staging system exists for HCC because not only tumor state but also liver function, PS and cancerrelated symptoms can determine the recommended treatment and the prognosis for patients [26] [27] [28] [29] . Each study selected some different clinical staging-based eligibility criteria for Annals of Oncology original article patient enrollment. Secondly, the radiological evaluation of intrahepatic tumor response is complicated by the variable pattern of HCC tumor growth. Thirdly, most patients who underwent chemotherapy received various prior treatments with the goals of palliating or curing HCC, and this can affect data collection, analysis and conclusion of studies. For example, when treating with TACE, the lesions which have retained lipiodol for >4 weeks are considered to be necrotic [30] . However, if lipiodol deposition is nonuniform or incomplete, it is difficult to judge tumor viability and necrosis. Fourthly, each study used different criteria for assessing and categorizing tumor responses. In the current study, 81.3% of all patients had received TACE before administration of the XP regimen. Advanced or inoperable HCC patients with one more extrahepatic metastatic lesion were selected for this study to improve the homogeneity of tumor staging, increase the precision of assessing tumor response and facilitate the evaluation of the chemotherapeutic potential of the XP regimen.
The XP regimen had an objective response rate (PR) of 6.3%, a disease control rate (PR + SD) of 34.4%, 2.0 months of TTP and 12.2 months of OS. This outcome was comparable to the outcomes of capecitabine and oxaliplatin combination chemotherapy [8] , which is a very similar combination with our regimen. In the current study, a poor patient prognosis may have correlated with extrahepatic dissemination (100%), PVT (31.3%) and AFP value (median 705 ng/ml). Some reports have indicated that the high serum concentration of AFP correlates with the poor prognosis for HCC patients [31] .
These results showed a wide gap between TTP (2.0 months) and OS (12.2 months). Other studies reported similar results for HCC [9, 32] ; however, the reason for this discrepancy is not known. The application of post-treatment modalities after first-line chemotherapy might be one of the possible causes of this result. In the current study, after the failure of XP, seven patients received only supportive care and others received a second-line chemotherapy (n = 16), palliative radiotherapy to metastatic lesions (n = 11), TACE (n = 8), RFA (n = 2), PEI (n = 1) and even metastasectomy (n = 1).
Of the 25 patients who had intrahepatic viable tumors during systemic chemotherapy, six patients received concurrent TACE during chemotherapy. TACE has become one of the most common treatments for unresectable HCC. However, the efficacy of TACE for the treatment of local intrahepatic tumors in patients with metastatic HCC is uncertain during systemic chemotherapy. Six patients with concurrent TACE had a significantly prolonged TTP (6.5 versus 1.5 months, P = 0.0002) and showed a tendency toward a better OS time (17.4 versus 7.0 months, P = 0.08). Clinical and demographic characteristics including age, etiology, PS, liver function, PVT and pre-AFP level were not different between the concurrent TACE group (n = 6) and the systemic chemotherapy-only group (n = 19). However, according to a recent prognostic index, the Chinese University Prognostic Index [33] including total bilirubin, ascites, alkaline phosphatase, AFP and asymptomatic disease on presentation, six patients (100%) in the concurrent TACE group were in low-risk group. In the systemic chemotherapy-only group, 14 (73.6%) patients were in low-risk group, four (21.1%) in intermediate-risk group and one (5.3%) in high-risk group. Future randomized studies, which have large numbers of patients with similar baseline prognostic scores, are warranted to evaluate the role of local tumor control in patients with metastatic HCC.
Regarding XP regimen toxicity, one patient stopped the XP regimen due to prolonged grade 3 gastrointestinal problems that included nausea. The other cases with grade 3 toxicity were tolerable to the patients.
In conclusion, based on the observed response rate and TTP, XP combination chemotherapy showed modest antitumor efficacy in patients with metastatic HCC as systemic first-line treatment. However, XP combination chemotherapy showed tolerable toxicity and demonstrated favorable OS time.
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